Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply

Affiliations

¹ Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY 10029, USA. Electronic address: dlbhattmd@post.harvard.edu.
² Department of Medicine, University of Chicago, Chicago, IL, USA.

Comment

Deepak L Bhatt et al. Lancet. 2023.

. 2023 Apr 22;401(10385):1337-1338.

doi: 10.1016/S0140-6736(23)00337-9.

¹ Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY 10029, USA. Electronic address: dlbhattmd@post.harvard.edu.
² Department of Medicine, University of Chicago, Chicago, IL, USA.

No abstract available

Comment on

Key questions regarding the SYMPLICITY HTN-3 trial.
Kjeldsen SE, Burnier M, Narkiewicz K, Kreutz R, Mancia G. Kjeldsen SE, et al. Lancet. 2023 Apr 22;401(10385):1336-1337. doi: 10.1016/S0140-6736(23)00340-9. Lancet. 2023. PMID: 37087164 No abstract available.
Key questions regarding the SYMPLICITY HTN-3 trial.
Tanemoto M. Tanemoto M. Lancet. 2023 Apr 22;401(10385):1337. doi: 10.1016/S0140-6736(23)00336-7. Lancet. 2023. PMID: 37087165 No abstract available.